RU2358738C2 - Лекарственные средства для лечения сахарного диабета - Google Patents

Лекарственные средства для лечения сахарного диабета Download PDF

Info

Publication number
RU2358738C2
RU2358738C2 RU2005127870/15A RU2005127870A RU2358738C2 RU 2358738 C2 RU2358738 C2 RU 2358738C2 RU 2005127870/15 A RU2005127870/15 A RU 2005127870/15A RU 2005127870 A RU2005127870 A RU 2005127870A RU 2358738 C2 RU2358738 C2 RU 2358738C2
Authority
RU
Russia
Prior art keywords
group
compound
coch
insulin
formula
Prior art date
Application number
RU2005127870/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005127870A (ru
Inventor
Такао ИКЕНОУЕ (JP)
Такао ИКЕНОУЕ
Йоко КАГЕЯМА (JP)
Йоко КАГЕЯМА
Юкио ИЙНО (JP)
Юкио ИЙНО
Нобуо КОНДО (JP)
Нобуо КОНДО
Original Assignee
Адзиномото Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адзиномото Ко., Инк. filed Critical Адзиномото Ко., Инк.
Publication of RU2005127870A publication Critical patent/RU2005127870A/ru
Application granted granted Critical
Publication of RU2358738C2 publication Critical patent/RU2358738C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2005127870/15A 2003-02-07 2004-02-06 Лекарственные средства для лечения сахарного диабета RU2358738C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-031088 2003-02-07
JP2003031088 2003-02-07

Publications (2)

Publication Number Publication Date
RU2005127870A RU2005127870A (ru) 2006-03-10
RU2358738C2 true RU2358738C2 (ru) 2009-06-20

Family

ID=32844288

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005127870/15A RU2358738C2 (ru) 2003-02-07 2004-02-06 Лекарственные средства для лечения сахарного диабета

Country Status (11)

Country Link
US (1) US7807663B2 (es)
EP (1) EP1595544A4 (es)
JP (1) JPWO2004069259A1 (es)
KR (1) KR20050097537A (es)
CN (2) CN1771040B (es)
AU (1) AU2004210268B8 (es)
BR (1) BRPI0407303A (es)
CA (1) CA2515294A1 (es)
MX (1) MXPA05008363A (es)
RU (1) RU2358738C2 (es)
WO (1) WO2004069259A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115852A (pt) * 2000-12-01 2003-12-23 Ajinomoto Kk Composto de lactama ou um seu sal farmaceuticamente aceitável, agente para aumentar a capacidade de transporte de açúcar, agentes hipoglicêmico e para prevenir e/ou tratar diabetes, neuropatia periférica diabética, nefropatia diabética, retinopatia diabética, macroangiopatia diabética, tolerância prejudicada à glicose ou adipose, e, composição farmacêutica
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
WO2006118341A1 (ja) 2005-04-28 2006-11-09 Ajinomoto Co., Inc. 新規ラクタム化合物
US20070009615A1 (en) * 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
US20070036874A1 (en) * 2005-08-05 2007-02-15 Litao Zhong Compositions and methods for controlling glucose and lipid uptake from foods
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
JP5672699B2 (ja) 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
KR101904920B1 (ko) * 2012-05-18 2018-10-08 (주)아모레퍼시픽 보글리보스를 포함하는 피부 미백용 조성물
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961377A (en) * 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL132376C (es) * 1966-02-10
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US20020099186A1 (en) * 2000-11-29 2002-07-25 Synsorb Biotech, Inc. Processes for the preparation of alphaGal(1-3)betaGal(1-4)Glc-OR
BR0115852A (pt) * 2000-12-01 2003-12-23 Ajinomoto Kk Composto de lactama ou um seu sal farmaceuticamente aceitável, agente para aumentar a capacidade de transporte de açúcar, agentes hipoglicêmico e para prevenir e/ou tratar diabetes, neuropatia periférica diabética, nefropatia diabética, retinopatia diabética, macroangiopatia diabética, tolerância prejudicada à glicose ou adipose, e, composição farmacêutica
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1985, ч.1, с.551, 562-563. *

Also Published As

Publication number Publication date
AU2004210268B2 (en) 2009-05-28
KR20050097537A (ko) 2005-10-07
RU2005127870A (ru) 2006-03-10
CN101822834A (zh) 2010-09-08
CN1771040B (zh) 2010-06-16
EP1595544A1 (en) 2005-11-16
CA2515294A1 (en) 2004-08-19
BRPI0407303A (pt) 2006-02-07
US20050272641A1 (en) 2005-12-08
EP1595544A4 (en) 2009-05-06
US7807663B2 (en) 2010-10-05
JPWO2004069259A1 (ja) 2006-05-25
AU2004210268A1 (en) 2004-08-19
CN1771040A (zh) 2006-05-10
WO2004069259A1 (ja) 2004-08-19
AU2004210268B8 (en) 2009-06-04
MXPA05008363A (es) 2005-12-06

Similar Documents

Publication Publication Date Title
US7807663B2 (en) Therapeutic agents for diabetes
KR102062824B1 (ko) 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
ES2376351T5 (es) Inhibidores de la dipeptidil-peptidasa para el tratamiento de la diabetes
KR101438234B1 (ko) 의약의 병용 및 그 용도
TWI412366B (zh) 二肽基肽酶抑制劑之週投與方法
BRPI0616077A2 (pt) administração de inibidores de dipeptidil peptidase
BRPI0616055B1 (pt) Composição farmacêutica formulada em forma de dose única

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120207